Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings
Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings
复制标题
DOI：
10.1186/1758-2652-13-42
复制
发表时间：
2010-11-03
影响因子：
6
通讯作者：
Manabe, Yukari C.
中科院分区：
文献类型：
--
作者：
Kiragga, Agnes N.;Castelnuovo, Barbara;Manabe, Yukari C.
背景：在乌干达，司他夫定不再被推荐作为开始抗逆转录病毒治疗（ART）的患者的一线治疗的一部分。大多数患者目前开始接受含齐多夫定的治疗方案，这可能导致贫血。我们调查了早期严重贫血的危险因素，在第一个六个月的ART initiation.Methods：我们定义基线（ART启动）贫血血红蛋白（Hb）
Background: Stavudine is no longer recommended as part of first-line therapy for patients initiating antiretroviral therapy (ART) in Uganda. Most patients are currently initiated on zidovudine-containing regimens, which can induce anaemia. We investigated the risk factors for early severe anaemia in the first six months of ART initiation.Methods: We defined baseline (ART initiation) anaemia as haemoglobin (Hb)